The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Ipsen and Kartos Therapeutics have signed a definitive merger agreement under which Ipsen will acquire Kartos Therapeutics, according to reports. The acquisition adds navtemadlin, an investigational MDM2 inhibitor designed to restore the tumor-suppressing function of p53 in myelofibrosis patients with suboptimal response to standard ruxolitinib therapy.
The deal comes amid a wave of M&A activity in hemato-oncology, as large pharma companies seek to bolster late-stage pipelines. The purchase price was not disclosed, limiting the market's ability to assess immediate financial impact. Per market data, Ipsen's Paris-listed shares (IPN.PA) closed at €162.40 on June 26, 2026, while its ADR (IPSEY) last traded at $46.50 on June 24, 2026.
Sign in to access this content
Sign InInvestors will watch for regulatory milestones and upcoming clinical data for navtemadlin, as FDA approval would be a key value driver. Technically, IPN.PA sits just below its recent high of €163.10, with potential support at €160. No near-term calendar events are directly tied to Ipsen, but trial readouts could act as price catalysts in the coming months.